ContextVision Announces Continued High Sales in 2016

Medical imaging leader displays strongest growth in company history, takes position in AI technology

STOCKHOLM – February 23, 2017 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, reported total sales of 9 million USD in 2016 – the highest sales year in the company’s history. This milestone for the imaging technology leader is a result of successful partnerships with OEM customers worldwide. The customization of the image enhancement software ensures optimal image quality, meeting the increasing demand for superior medical imaging in healthcare.

“Over the course of the past year, we have continued to develop our partnerships and increased our customer base, serving the ever evolving needs of the medical imaging industry,” said Fredrik Palm, vice president, ContextVision. “Our mission is to drive innovation in medical imaging to deliver the highest quality imaging solutions, and we anticipate continued success going forward.”

During the latest years ContextVision has invested in AI to provide new future proof solutions to empower healthcare. This was proven in the TUPAC 2016 competition where ContextVision placed second with its deep learning technology.

“Deep learning is a hot technology within artificial intelligence,” said Palm. “While many companies are in the process of learning the technology, ContextVision has invested in moving to the forefront of knowledge in deep learning.”

About ContextVision
ContextVision’s cutting-edge technology helps doctors more accurately interpret medical images, a crucial foundation for better diagnosis and treatment. An industry pioneer for more than 30 years, the company’s state-of-the-art medical image analysis and enhancement software for 2D/3D/4D Ultrasound, MRI, X-Ray and Mammography is used by leading equipment manufacturers worldwide. ContextVision continues to invest heavily in R&D in order to expand its technology platform. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit

Press Contact

Fredrik Palm
Vice President
Phone: +46 76 870 25 43